Herceptin
Company: Genentech
Approval Status: Approved October 1998
Treatment for: Breast cancer
Areas: Endocrinology; Obstetrics/Gynecology; Oncology
General Information
Other Useful Resources
Herceptin (trastuzumab) is used as a second- or third-line therapy for patients with metastatic breast cancer.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Medical Dictionary Searches
